Latest News

Ixekizumab Yields Early, Sustained Improvements to Quality of Life Measures in Pediatric Patients With Plaque Psoriasis
Ixekizumab Yields Early, Sustained Improvements to Quality of Life Measures in Pediatric Patients With Plaque Psoriasis

July 12th 2024

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Crystal Structure of Bimekizumab Fab Fragment Supports Efficacy of IL-17 Dual Inhibition
Crystal Structure of Bimekizumab Fab Fragment Supports Efficacy of IL-17 Dual Inhibition

July 9th 2024

Deucravacitinib Shows Promise as Oral Psoriasis Treatment
Deucravacitinib Shows Promise as Oral Psoriasis Treatment

July 5th 2024

VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease
VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease

July 3rd 2024

FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine
FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine

July 1st 2024

© 2024 MJH Life Sciences

All rights reserved.